How the Orphan Drug Act Has Changed the Rare Disease Landscape | CheckRare.com
Badhiu Basu, PhD, owner of the Converge Advisory Group talked about the Orphan Drug Act and what it has (and has not) accomplished.
Related Articles
Plans for a Phase 3 Clinical Trial Evaluating FLT201 in Patients With Gaucher Disease
Reena Sharma, MD, discusses plans for a phase 3 clinical trial evaluating FLT201 in patients with Gaucher disease.
Optimizing Therapeutic Proteins Through PEGylation: Key Parameters and Impacts
This Webinar examines what is PEGylation and the clinical uses of therapeutic proteins, and their applications in healthcare.
Neuroblastoma
Neuroblastoma is a rare childhood cancer characterized by a neuroendocrine tumor originating in neuroblasts or neural crest progenitor cells.
Effectiveness of Idursulfase in Patients With MPS II
Barbara Burton, MD, discusses a recent study examining the effectiveness of idursulfase in young patients with MPS II.
Arginine Vasopressin (AVP) Deficiency
AVP deficiency is a rare neuroendocrine disorder caused by impaired function of vasopressinergic neurons in the hypothalamus and posterior pituitary gland.
Complement-Mediated Kidney Disorders: A Case Series
Three case studies exploring complexities of diagnosing, treating, and managing patients with various complement-mediated kidney disorders.
Erdheim-Chester Disease
Erdheim-Chester disease is a rare condition affecting many parts of the body, it most commonly affects adults.
PAH Clinical Research Highlights: CHEST 2024
Jean Elwing discusses PAH research leading to better management of people with Pulmonary Arterial Hypertension
Results from the MajesTEC-2 and TRIMM-2 Clinical Trials for Patients With Multiple Myeloma
Anita D’Souza, MD, discusses results from the MajesTEC-2 and TRIMM-2 clinical trials for tec-DP in patients with multiple myeloma.
Improving Health Equity in Hereditary Angioedema (HAE): A Panel Discussion
Drs. Aleena Banerji, Timothy Craig, and Marc Riedl, provide an overview of the discrepancies and discuss improving health equity in HAE.